177 related articles for article (PubMed ID: 38181323)
21. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review and a Meta-analysis of Randomized Controlled Trials' Control Groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Napoli G; Arcangeli S; Fionda B; Munoz F; Tebano U; Durante E; Tucci M; Bortolus R; Muraro M; Rinaldi G; Luca N; Fiorica F
Curr Oncol Rep; 2022 Nov; 24(11):1633-1644. PubMed ID: 35953601
[TBL] [Abstract][Full Text] [Related]
23. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
[TBL] [Abstract][Full Text] [Related]
24. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
[TBL] [Abstract][Full Text] [Related]
25. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis.
Jian T; Zhan Y; Hu K; He L; Chen S; Hu R; Lu J
Front Pharmacol; 2022; 13():955925. PubMed ID: 36278154
[No Abstract] [Full Text] [Related]
26. Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice.
Lendorf ME; Petersen PM; Svendsen AS; Lindberg H; Brasso K
Eur Urol Open Sci; 2021 Feb; 24():25-33. PubMed ID: 34337492
[TBL] [Abstract][Full Text] [Related]
27. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
[TBL] [Abstract][Full Text] [Related]
28. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
30. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G
Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225
[TBL] [Abstract][Full Text] [Related]
31. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract][Full Text] [Related]
33. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
34. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
35. [TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)].
Merseburger AS; Suttmann H
Aktuelle Urol; 2021 Apr; 52(2):155-160. PubMed ID: 33113571
[TBL] [Abstract][Full Text] [Related]
36. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Vale CL; Fisher DJ; Godolphin PJ; Rydzewska LH; Boher JM; Burdett S; Chen YH; Clarke NW; Fizazi K; Gravis G; James ND; Liu G; Matheson D; Murphy L; Oldroyd RE; Parmar MKB; Rogozinska E; Sfumato P; Sweeney CJ; Sydes MR; Tombal B; White IR; Tierney JF;
Lancet Oncol; 2023 Jul; 24(7):783-797. PubMed ID: 37414011
[TBL] [Abstract][Full Text] [Related]
37. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
38. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
40. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
